178 related articles for article (PubMed ID: 15165713)
1. The bombesin/gastrin releasing peptide receptor antagonist RC-3095 blocks apomorphine but not MK-801-induced stereotypy in mice.
Meller CA; Henriques JA; Schwartsmann G; Roesler R
Peptides; 2004 Apr; 25(4):585-8. PubMed ID: 15165713
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
Szepeshazi K; Schally AV; Cai RZ; Radulovic S; Milovanovic S; Szoke B
Cancer Res; 1991 Nov; 51(21):5980-6. PubMed ID: 1682039
[TBL] [Abstract][Full Text] [Related]
3. Opposite effects of low and high doses of the gastrin-releasing peptide receptor antagonist RC-3095 on memory consolidation in the hippocampus: possible involvement of the GABAergic system.
Dantas Ados S; Luft T; Henriques JA; Schwartsmann G; Roesler R
Peptides; 2006 Sep; 27(9):2307-12. PubMed ID: 16650508
[TBL] [Abstract][Full Text] [Related]
4. Non-associative learning and anxiety in rats treated with a single systemic administration of the gastrin-releasing peptide receptor antagonist RC-3095.
Martins MR; Reinke A; Valvassori SS; Machado RA; Quevedo J; Schwartsmann G; Roesler R
Peptides; 2005 Dec; 26(12):2525-9. PubMed ID: 16023260
[TBL] [Abstract][Full Text] [Related]
5. Effects of intracerebral ventricular administration of gastrin-releasing peptide and its receptor antagonist RC-3095 on learned fear responses in the rat.
Merali Z; Mountney C; Kent P; Anisman H
Behav Brain Res; 2011 Jan; 216(2):519-24. PubMed ID: 20801162
[TBL] [Abstract][Full Text] [Related]
6. A gastrin-releasing peptide receptor antagonist blocks D-amphetamine-induced hyperlocomotion and increases hippocampal NGF and BDNF levels in rats.
Kauer-Sant'Anna M; Andreazza AC; Valvassori SS; Martins MR; Barbosa LM; Schwartsmann G; Roesler R; Quevedo J; Kapczinski F
Peptides; 2007 Jul; 28(7):1447-52. PubMed ID: 17629354
[TBL] [Abstract][Full Text] [Related]
7. Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
Szepeshazi K; Schally AV; Rick FG; Block NL; Vidaurre I; Halmos G; Szalontay L
Anticancer Drugs; 2012 Oct; 23(9):906-13. PubMed ID: 22926257
[TBL] [Abstract][Full Text] [Related]
8. Differential activation of human gastrin-releasing peptide receptor-mediated responses by bombesin analogs.
Wu JM; Hoang DO; Feldman RI
Mol Pharmacol; 1995 Apr; 47(4):871-81. PubMed ID: 7723750
[TBL] [Abstract][Full Text] [Related]
9. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Pinski J; Halmos G; Szepeshazi K; Schally AV
Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
[TBL] [Abstract][Full Text] [Related]
10. Dexamethasone reverses the memory impairment induced by antagonism of hippocampal gastrin-releasing peptide receptors.
Venturella R; Lessa D; Luft T; Roozendaal B; Schwartsmann G; Roesler R
Peptides; 2005 May; 26(5):821-5. PubMed ID: 15808912
[TBL] [Abstract][Full Text] [Related]
11. Characterization of bombesin receptors using a novel, potent, radiolabeled antagonist that distinguishes bombesin receptor subtypes.
Mantey S; Frucht H; Coy DH; Jensen RT
Mol Pharmacol; 1993 May; 43(5):762-74. PubMed ID: 7684815
[TBL] [Abstract][Full Text] [Related]
12. Endocrine effects of new bombesin/gastrin-releasing peptide antagonists in rats.
Pinski J; Yano T; Groot K; Cai RZ; Radulovic S; Schally AV
Am J Physiol; 1992 Oct; 263(4 Pt 1):E712-7. PubMed ID: 1415689
[TBL] [Abstract][Full Text] [Related]
13. The neurotensin agonist NT69L improves sensorimotor gating deficits in rats induced by a glutamatergic antagonist, but not by dopaminergic agonists.
Secchi RL; Sung E; Hedley LR; Button D; Schreiber R
Behav Brain Res; 2009 Sep; 202(2):192-7. PubMed ID: 19463701
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
Kahán Z; Sun B; Schally AV; Arencibia JM; Cai RZ; Groot K; Halmos G
Cancer; 2000 Mar; 88(6):1384-92. PubMed ID: 10717621
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide.
Kiaris H; Schally AV; Sun B; Armatis P; Groot K
Oncogene; 1999 Nov; 18(50):7168-73. PubMed ID: 10597318
[TBL] [Abstract][Full Text] [Related]
16. Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
Szepeshazi K; Schally AV; Groot K; Halmos G
Int J Cancer; 1993 May; 54(2):282-9. PubMed ID: 8387464
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV
Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro.
Qin Y; Ertl T; Cai RZ; Halmos G; Schally AV
Cancer Res; 1994 Feb; 54(4):1035-41. PubMed ID: 8313359
[TBL] [Abstract][Full Text] [Related]
19. Effects of an antagonist of the gastrin-releasing peptide receptor in an animal model of uveitis.
Pereira DV; Steckert AV; Mina F; Petronilho F; Roesler R; Schwartsmann G; Ritter C; Dal-Pizzol F
Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5300-3. PubMed ID: 19516017
[TBL] [Abstract][Full Text] [Related]
20. Gastrin-releasing peptide induces itch-related responses through mast cell degranulation in mice.
Andoh T; Kuwazono T; Lee JB; Kuraishi Y
Peptides; 2011 Oct; 32(10):2098-103. PubMed ID: 21933692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
